Teduglutide in Crohn's disease

Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure

(2012) Palle B. Jeppesen et al.   GASTROENTEROLOGY

GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

(2012) Susan E. Alters et al.   PLoS One

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

(2011) P. B. Jeppesen et al.   GUT

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohnʼs disease

(2009) Alan L. Buchman et al.   INFLAMMATORY BOWEL DISEASES

Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's Disease

(2009) Jean-Francois Marier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects

(2008) Jean-Francois Marier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET